Keel Point LLC Decreases Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Keel Point LLC lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,175 shares of the medical research company’s stock after selling 342 shares during the quarter. Keel Point LLC’s holdings in Thermo Fisher Scientific were worth $3,743,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Savant Capital LLC increased its holdings in shares of Thermo Fisher Scientific by 0.5% in the 4th quarter. Savant Capital LLC now owns 3,627 shares of the medical research company’s stock valued at $1,997,000 after acquiring an additional 18 shares during the period. Connecticut Wealth Management LLC increased its stake in Thermo Fisher Scientific by 3.0% in the first quarter. Connecticut Wealth Management LLC now owns 614 shares of the medical research company’s stock valued at $354,000 after purchasing an additional 18 shares during the period. Sage Rhino Capital LLC grew its position in Thermo Fisher Scientific by 2.6% in the 1st quarter. Sage Rhino Capital LLC now owns 723 shares of the medical research company’s stock valued at $417,000 after buying an additional 18 shares during the last quarter. 1776 Wealth LLC raised its position in Thermo Fisher Scientific by 2.4% during the 4th quarter. 1776 Wealth LLC now owns 799 shares of the medical research company’s stock worth $440,000 after buying an additional 19 shares during the last quarter. Finally, Crumly & Associates Inc. boosted its holdings in shares of Thermo Fisher Scientific by 1.5% in the first quarter. Crumly & Associates Inc. now owns 1,274 shares of the medical research company’s stock valued at $734,000 after acquiring an additional 19 shares in the last quarter. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of analyst reports. StockNews.com raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Friday. Robert W. Baird lowered their price target on shares of Thermo Fisher Scientific from $664.00 to $625.00 and set an “outperform” rating on the stock in a research report on Thursday, July 27th. Barclays raised their target price on shares of Thermo Fisher Scientific from $590.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, July 27th. KeyCorp cut their price target on Thermo Fisher Scientific from $710.00 to $640.00 in a report on Thursday, May 25th. Finally, Raymond James upped their price objective on shares of Thermo Fisher Scientific from $595.00 to $630.00 and gave the company an “outperform” rating in a research note on Friday, July 28th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $631.71.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $549.00, for a total value of $5,490,000.00. Following the sale, the chief executive officer now owns 141,330 shares of the company’s stock, valued at approximately $77,590,170. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 3,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $557.77, for a total transaction of $1,673,310.00. Following the sale, the executive vice president now owns 17,556 shares of the company’s stock, valued at approximately $9,792,210.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $549.00, for a total value of $5,490,000.00. Following the transaction, the chief executive officer now directly owns 141,330 shares in the company, valued at $77,590,170. The disclosure for this sale can be found here. Insiders have sold 28,700 shares of company stock valued at $15,799,270 over the last quarter. Insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.6 %

TMO stock traded down $3.15 during trading on Tuesday, reaching $504.58. The stock had a trading volume of 324,781 shares, compared to its average volume of 1,493,450. Thermo Fisher Scientific Inc. has a 1-year low of $475.77 and a 1-year high of $609.85. The company has a current ratio of 1.42, a quick ratio of 1.02 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $194.74 billion, a P/E ratio of 34.72, a PEG ratio of 2.43 and a beta of 0.77. The firm has a fifty day moving average price of $540.37 and a 200 day moving average price of $541.53.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 26th. The medical research company reported $5.15 earnings per share for the quarter, missing the consensus estimate of $5.43 by ($0.28). The company had revenue of $10.69 billion during the quarter, compared to the consensus estimate of $10.99 billion. Thermo Fisher Scientific had a return on equity of 18.59% and a net margin of 13.14%. Thermo Fisher Scientific’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same period in the previous year, the firm posted $5.51 EPS. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 22.37 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 13th. Stockholders of record on Friday, September 15th will be issued a $0.35 dividend. This represents a $1.40 annualized dividend and a dividend yield of 0.28%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.57%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.